Gefitinib-induced interstitial pneumonia: A case report and review of the literature

Luo, Changqin; Lv, Meiling; Li, Yuyao; Liu, Peijun; Yang, Jin Hyuk

doi:10.3892/etm.2014.1495

Cited by 8 publications

(7 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Interstitial lung disease has been observed as a serious adverse side effect for gefitinib ( 147 ), with a 0.3% incidence in the U.S. and a 2% incidence in Japan. The median onset of gefitinib-induced interstitial pneumonia in the U.S. was 42 days, and in Japan was 24 days, with around one-third of all cases caused by gefitinib being fatal ( 148 ).…”

Section: Erlotinib and Gefitinibmentioning

confidence: 99%

Repurposing of Kinase Inhibitors for Treatment of COVID-19

et al. 2020

View full text Add to dashboard Cite

The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the scientific community. In the absence of a vaccine, the goal is to target the viral life cycle and alleviate the lung-damaging symptoms of infection, which can be lifethreatening. There are numerous protein kinases associated with these processes that can be inhibited by FDA-approved drugs, the repurposing of which presents an alluring option as they have been thoroughly vetted for safety and are more readily available for treatment of patients and testing in clinical trials. Here, we characterize more than 30 approved kinase inhibitors in terms of their antiviral potential, due to their measured potency against key kinases required for viral entry, metabolism, or reproduction. We also highlight inhibitors with potential to reverse pulmonary insufficiency because of their anti-inflammatory activity, cytokine suppression, or antifibrotic activity. Certain agents are projected to be dualpurpose drugs in terms of antiviral activity and alleviation of disease symptoms, however drug combination is also an option for inhibitors with optimal pharmacokinetic properties that allow safe and efficacious co-administration with other drugs, such as antiviral agents, IL-6 blocking agents, or other kinase inhibitors.

show abstract

Section: Erlotinib and Gefitinibmentioning

confidence: 99%

Repurposing of Kinase Inhibitors for Treatment of COVID-19

et al. 2020

View full text Add to dashboard Cite

show abstract

“…At present, target therapy drugs are widely used, and increasingly, rare adverse reactions are emerging, although recommended guidelines are not updated in time (1)(2)(3). This requires clinical case sharing to obtain clinical evidence for reasonable and effective intervention (4,5).…”

Section: Introductionmentioning

confidence: 99%

Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report

Xiao¹,

Ruan²,

Ning³

et al. 2021

Transl Cancer Res TCR

View full text Add to dashboard Cite

Epidermal growth factor receptor (EGFR) inhibitors, as a first-line drug treatment in the EGFRsensitive mutation of advanced non-small-cell lung cancer (NSCLC), has been used in a wide variety of malignancies. These therapies have various troublesome side effects including diarrhea, stomatitis, mucositis, rash, dry skin and paronychia which may impact a patient's clinical outcome in addition to their beneficial effects. Here, we report a rare case of a 69-year-old male having advanced NCSLC treated with gefitinib, who developed EGFR tyrosine kinase inhibitor (TKI)-related multiple ulcers accompanied by bleeding.After a detailed examination and multidisciplinary discussion, we have learnt that early identification of gastrointestinal (GI) bleeding and blood in urine is due to targeted drugs rather than other causes such as ulcer and stones. Good results have also been achieved by reducing drug dosage under close observation.So far, the patient has been followed up for 15 months, and his condition remained stable. Up to now, there is no case of such severe side effect having been found, and no guidelines recommended for handling such adverse events. Through clinical case sharing, early recognition and proactive management are particularly important in order to minimize appropriately the effect of these adverse events. The whole course of a disease can be vividly illustrated through a case report, so as to provide more effective guiding principles for clinicians.

show abstract

“…Once patients suffered from rapidly progressive symptoms or more severe symptoms, high-dose steroid therapy (≥ 2 mg/kg/day methylprednisolone) should be used [6,47]. In patients with impending respiratory failure or respiratory failure requiring mechanical ventilation, administratoin of intravenous methylprednisolone up to 500-1000 mg/day for 3 days had been demonstrated in the anecdotal reports [44,47,49]. If clinical symptoms are improved, the dose of corticosteroid should be tapered gradually.…”

Section: Diagnosis and Management Of Targeted Therapyinduced Ildmentioning

confidence: 99%

“…The main managment of targeted therapyinduced ILD includes drug discontinuation, corticosteroid therapy, and supportive care [4,48,49]. Diagnosis of significant ILD justifies discontinuation of the culprit causing pulmonayr toxicities.…”

Section: Diagnosis and Management Of Targeted Therapyinduced Ildmentioning

confidence: 99%

Interstitial Lung Disease Induced by Targeted Therapy for Non-Small Cell Lung Cancer: A Review of Diagnosis, Workup, and Management

Chen

Luo²

2014

J Palliat Care Med

View full text Add to dashboard Cite

Targeted therapies are being increasingly used for cancer treatments and had been proven to improve clinical outcomes. Although targeted therapies demonstrate survival benefit in particular patient populations, they may also increase the frequency of treatment-related toxicities and morbidity. The pulmonary toxicities, especially drug induced-interstitial lung disease (ILD), have emerged as critical adverse drug reactions which are potentially fatal. The main managment of targeted therapy-induced ILD includes drug discontinuation and corticosteroid therapy, but no standard guideline for the treatment of targeted therapy-induced ILD was established. Clinical physicians must cautiously weigh the benefits and risks of targeted therapies causing ILD in order to provide optimal treatments and favorable outcomes. Relevant clinical information regarding management of targeted therapy-induced ILD was reviewed in this article.

show abstract

Gefitinib-induced interstitial pneumonia: A case report and review of the literature

Cited by 8 publications

References 25 publications

Repurposing of Kinase Inhibitors for Treatment of COVID-19

Repurposing of Kinase Inhibitors for Treatment of COVID-19

Bleeding with gastrointestinal and ureteral ulcers after gefitinib treatment: a case report

Interstitial Lung Disease Induced by Targeted Therapy for Non-Small Cell Lung Cancer: A Review of Diagnosis, Workup, and Management

Contact Info

Product

Resources

About